In addition, Zealand and Roche are developing petrelintide as standalone treatment and in combinations, including a program with Roche's incretin candidate CT-388
Regular review helps assess tolerance, results, safety, and whether the treatment plan should continue or change
If you and your doctor decide to transition from injections to oral therapy, two things are essential for your safety: Strict Daily Adherence : Because passive diffusion relies on a daily supply of B12, missing your pill frequently puts you at a higher risk of relapse compared to receiving a guaranteed intramuscular injection [14]
At night, its a good idea to switch things up with the Arencia Retinal Booster Shot
JAMA 272, 14131420
The SURMOUNT phase 3 program (SURMOUNT-1, NCT04184622) studied tirzepatide in adults with obesity or overweight without type 2 diabetes, with body weight as the primary endpoint over 72 weeks